Markets:

Overview

News

Currencies

International

Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

5.480 -0.080 (-1.44%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday ↗

March 27, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

UBS, Credit Suisse And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

March 24, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday ↗

March 23, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Earnings Outlook For Aldeyra Therapeutics ↗

March 08, 2023

Via Benzinga

Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder ↗

October 06, 2022

Via Benzinga

Recap: Aldeyra Therapeutics Q2 Earnings ↗

August 05, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial ↗

July 12, 2022

Via Benzinga

Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients ↗

February 28, 2023

Via Benzinga

Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough ↗

February 23, 2023

An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...

Via Benzinga

Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication ↗

December 13, 2022

Via Benzinga

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary ↗

September 14, 2022

Via Benzinga

$2 Million Bet On This Industrial Stock? 4 Stocks Insiders Are Buying ↗

August 08, 2022

Although US stocks closed mixed on Friday, there were a few notable insider trades.

Via Benzinga

Why Aldeyra Therapeutics' Shares Are Soaring Today? ↗

June 08, 2022

Via Benzinga

Aldeyra Therapeutics: Q1 Earnings Insights ↗

May 05, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For August 5, 2022 ↗

August 05, 2022

Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.

Via Benzinga

Earnings Outlook For Aldeyra Therapeutics ↗

August 04, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Aldeyra...

Via Benzinga

Boeing, PriceSmart And 80 Biggest Movers From Yesterday ↗

July 13, 2022

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 12, 2022

Via Benzinga

The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner ↗

July 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 12, 2022

Via Benzinga

Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness ↗

May 18, 2022

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

70 Biggest Movers From Friday ↗

May 02, 2022

Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 29, 2022

Via Benzinga

48 Stocks Moving In Friday's Mid-Day Session ↗

April 29, 2022

Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:...

Via Benzinga

Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points ↗

April 29, 2022

U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Friday.

Via Benzinga

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid ↗

April 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 29, 2022

Via Benzinga

How To Attend Aldeyra Therapeutics Q1 2022 Earnings Conference Call ↗

April 29, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

Headline News about Aldeyra Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today